1162 related articles for article (PubMed ID: 17041910)
1. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
2. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
3. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
4. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
[TBL] [Abstract][Full Text] [Related]
5. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
7. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
8. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.
Madden HR; Fletcher S; Davis MR; Wilton SD
Hum Mutat; 2009 Jan; 30(1):22-8. PubMed ID: 18570328
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
11. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion.
Ferreiro V; Giliberto F; Muñiz GM; Francipane L; Marzese DM; Mampel A; Roqué M; Frechtel GD; Szijan I
Muscle Nerve; 2009 Feb; 39(2):239-43. PubMed ID: 19012301
[TBL] [Abstract][Full Text] [Related]
14. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
15. Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene.
Miyazaki D; Yoshida K; Fukushima K; Nakamura A; Suzuki K; Sato T; Takeda S; Ikeda S
J Hum Genet; 2009 Feb; 54(2):127-30. PubMed ID: 19158820
[TBL] [Abstract][Full Text] [Related]
16. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
[TBL] [Abstract][Full Text] [Related]
18. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
Matsuo M
IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
[TBL] [Abstract][Full Text] [Related]
19. Point mutations in Czech DMD/BMD patients and their phenotypic outcome.
Sedlácková J; Vondrácek P; Hermanová M; Zámecník J; Hrubá Z; Haberlová J; Kraus J; Maríková T; Hedvicáková P; Vohánka S; Fajkusová L
Neuromuscul Disord; 2009 Nov; 19(11):749-53. PubMed ID: 19783145
[TBL] [Abstract][Full Text] [Related]
20. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]